Which has better valuation & earnings, DRMA or HOWL?

Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A Werewolf Therapeutics N/A N/A -$60.82M -$1.24 N/A

Is DRMA or HOWL more profitable?

Dermata Therapeutics' return on equity of -127.91% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dermata Therapeutics N/A -127.91% -105.05% Werewolf Therapeutics N/A -208.23% -75.12%

Do analysts prefer DRMA or GRDX?

Dermata Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 726.45%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dermata Therapeutics is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is DRMA or GRDX more profitable?

Entero Therapeutics' return on equity of -49.81% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dermata Therapeutics N/A -127.91% -105.05% Entero Therapeutics N/A -49.81% -11.02%

Which has higher valuation & earnings, DRMA or CLRB?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is DRMA or CLRB more profitable?

Dermata Therapeutics' return on equity of -127.91% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Dermata Therapeutics N/A -127.91% -105.05% Cellectar Biosciences N/A -349.24% -153.18%

Which has preferable valuation and earnings, DRMA or MDCX?

Dermata Therapeutics is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is DRMA or MDCX more profitable?

Dermata Therapeutics' return on equity of -127.91% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Dermata Therapeutics N/A -127.91% -105.05% Medicus Pharma N/A -3,137.84% -311.33%

Do analysts prefer DRMA or QNTM?

Dermata Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 726.45%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dermata Therapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, DRMA or QNTM?

Quantum Biopharma is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is DRMA or QNTM more profitable?

Dermata Therapeutics' return on equity of -127.91% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Dermata Therapeutics N/A -127.91% -105.05% Quantum Biopharma N/A -941.54% -224.41%

Dermata Therapeutics (DRMA) Competitors

$1.21 +0.03 (+2.54%)

Closing price 04:00 PM Eastern

Extended Trading

$1.25 +0.04 (+2.89%)

As of 07:16 PM Eastern

Compare

DRMA vs. HOWL, GRDX, CLRB, MDCX, and QNTM

Should you buy Dermata Therapeutics stock or one of its competitors? MarketBeat compares Dermata Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dermata Therapeutics include Werewolf Therapeutics (HOWL), Entero Therapeutics (GRDX), Cellectar Biosciences (CLRB), Medicus Pharma (MDCX), and Quantum Biopharma (QNTM). These companies are all part of the "pharmaceutical products" industry.

How does Dermata Therapeutics compare to Werewolf Therapeutics?

Dermata Therapeutics (NASDAQ:DRMA) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Werewolf Therapeutics had 8 more articles in the media than Dermata Therapeutics. MarketBeat recorded 8 mentions for Werewolf Therapeutics and 0 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.18 indicating that Dermata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Werewolf Therapeutics	Neutral

Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
Werewolf Therapeutics	N/A	N/A	-$60.82M	-$1.24	N/A

Dermata Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 21.9% of Dermata Therapeutics shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dermata Therapeutics' return on equity of -127.91% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

Dermata Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 726.45%. Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 881.93%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Dermata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Werewolf Therapeutics beats Dermata Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Dermata Therapeutics compare to Entero Therapeutics?

Dermata Therapeutics (NASDAQ:DRMA) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Entero Therapeutics has higher revenue and earnings than Dermata Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
Entero Therapeutics	$40K	1,034.08	-$6.39M	-$1.88	N/A

Dermata Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 726.45%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dermata Therapeutics is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Entero Therapeutics' return on equity of -49.81% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
Entero Therapeutics	N/A	-49.81%	-11.02%

In the previous week, Dermata Therapeutics' average media sentiment score of 0.00 equaled Entero Therapeutics'average media sentiment score.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Entero Therapeutics	Neutral

Dermata Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Entero Therapeutics beats Dermata Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Dermata Therapeutics compare to Cellectar Biosciences?

Dermata Therapeutics (NASDAQ:DRMA) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

In the previous week, Cellectar Biosciences' average media sentiment score of 0.34 beat Dermata Therapeutics' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Cellectar Biosciences	Neutral

Dermata Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dermata Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 726.45%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 338.25%. Given Dermata Therapeutics' higher probable upside, research analysts plainly believe Dermata Therapeutics is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Dermata Therapeutics' return on equity of -127.91% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Summary

Dermata Therapeutics beats Cellectar Biosciences on 8 of the 12 factors compared between the two stocks.

How does Dermata Therapeutics compare to Medicus Pharma?

Dermata Therapeutics (NASDAQ:DRMA) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Dermata Therapeutics' return on equity of -127.91% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Dermata Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.14, indicating that its share price is 86% less volatile than the broader market.

Dermata Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 726.45%. Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,576.98%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Dermata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

8.7% of Dermata Therapeutics shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by insiders. Comparatively, 8.1% of Medicus Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dermata Therapeutics is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

In the previous week, Medicus Pharma had 11 more articles in the media than Dermata Therapeutics. MarketBeat recorded 11 mentions for Medicus Pharma and 0 mentions for Dermata Therapeutics. Medicus Pharma's average media sentiment score of 0.13 beat Dermata Therapeutics' score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Medicus Pharma	Neutral

Summary

Medicus Pharma beats Dermata Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Dermata Therapeutics compare to Quantum Biopharma?

Dermata Therapeutics (NASDAQ:DRMA) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dermata Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Dermata Therapeutics' return on equity of -127.91% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
Quantum Biopharma	N/A	-941.54%	-224.41%

Quantum Biopharma is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Dermata Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 726.45%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dermata Therapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Quantum Biopharma had 7 more articles in the media than Dermata Therapeutics. MarketBeat recorded 7 mentions for Quantum Biopharma and 0 mentions for Dermata Therapeutics. Quantum Biopharma's average media sentiment score of 0.38 beat Dermata Therapeutics' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Quantum Biopharma	Neutral

Summary

Dermata Therapeutics beats Quantum Biopharma on 11 of the 13 factors compared between the two stocks.

Get Dermata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRMA vs. The Competition

Export

Metric	Dermata Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.86M	$3.30B	$6.43B	$12.05B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-0.23	18.93	23.75	23.75
Price / Sales	N/A	176.74	480.27	84.51
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	0.55	8.04	10.28	6.78
Net Income	-$7.56M	$23.89M	$3.57B	$337.51M
7 Day Performance	-9.70%	-5.97%	-1.43%	-2.72%
1 Month Performance	-3.97%	2.78%	3.27%	1.87%
1 Year Performance	-83.76%	36.26%	23.37%	26.61%

Dermata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRMA Dermata Therapeutics	2.8188 of 5 stars	$1.21 +2.5%	$10.00 +726.4%	-84.2%	$4.86M	N/A	N/A	8	Gap Up
HOWL Werewolf Therapeutics	3.7626 of 5 stars	$0.44 +2.9%	$3.75 +747.3%	-72.4%	$21.51M	$1.88M	N/A	40
GRDX Entero Therapeutics	0.585 of 5 stars	$6.34 -2.0%	N/A	N/A	$21.30M	$40K	N/A	9	Gap Up
CLRB Cellectar Biosciences	3.6257 of 5 stars	$2.61 -4.7%	$11.00 +321.5%	-76.1%	$20.85M	N/A	N/A	10
MDCX Medicus Pharma	2.7485 of 5 stars	$0.36 +8.8%	$9.00 +2,374.6%	-87.3%	$20.61M	N/A	N/A	N/A	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRMA) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dermata Therapeutics (DRMA) Competitors

DRMA vs. HOWL, GRDX, CLRB, MDCX, and QNTM

How does Dermata Therapeutics compare to Werewolf Therapeutics?

Summary

How does Dermata Therapeutics compare to Entero Therapeutics?

Summary

How does Dermata Therapeutics compare to Cellectar Biosciences?

Summary

How does Dermata Therapeutics compare to Medicus Pharma?

Summary

How does Dermata Therapeutics compare to Quantum Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA vs. The Competition

Dermata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dermata Therapeutics (DRMA) Competitors

DRMA vs. HOWL, GRDX, CLRB, MDCX, and QNTM

How does Dermata Therapeutics compare to Werewolf Therapeutics?

Does the media prefer DRMA or HOWL?

Which has better valuation & earnings, DRMA or HOWL?

Which has more volatility & risk, DRMA or HOWL?

Do insiders & institutionals have more ownership in DRMA or HOWL?

Is DRMA or HOWL more profitable?

Do analysts recommend DRMA or HOWL?

Summary

How does Dermata Therapeutics compare to Entero Therapeutics?

Which has higher valuation and earnings, DRMA or GRDX?

Do analysts prefer DRMA or GRDX?

Is DRMA or GRDX more profitable?

Does the media favor DRMA or GRDX?

Which has more volatility and risk, DRMA or GRDX?

Do insiders & institutionals have more ownership in DRMA or GRDX?

Summary

How does Dermata Therapeutics compare to Cellectar Biosciences?

Does the media prefer DRMA or CLRB?

Which has more risk & volatility, DRMA or CLRB?

Do institutionals and insiders hold more shares of DRMA or CLRB?

Do analysts rate DRMA or CLRB?

Which has higher valuation & earnings, DRMA or CLRB?

Is DRMA or CLRB more profitable?

Summary

How does Dermata Therapeutics compare to Medicus Pharma?

Is DRMA or MDCX more profitable?

Which has more volatility & risk, DRMA or MDCX?

Do analysts rate DRMA or MDCX?

Do insiders and institutionals hold more shares of DRMA or MDCX?

Which has preferable valuation and earnings, DRMA or MDCX?

Does the media favor DRMA or MDCX?

Summary

How does Dermata Therapeutics compare to Quantum Biopharma?

Do insiders & institutionals hold more shares of DRMA or QNTM?

Which has more volatility & risk, DRMA or QNTM?

Is DRMA or QNTM more profitable?

Which has stronger valuation & earnings, DRMA or QNTM?

Do analysts prefer DRMA or QNTM?

Does the media prefer DRMA or QNTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA vs. The Competition

Dermata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools